{"id":169071,"date":"2025-07-09T05:56:15","date_gmt":"2025-07-09T09:56:15","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169071"},"modified":"2025-07-09T05:56:15","modified_gmt":"2025-07-09T09:56:15","slug":"emcure-pharmaceuticals-ltd-q4fy25-63-rise-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-ltd-q4fy25-63-rise-in-profits\/","title":{"rendered":"Emcure Pharmaceuticals Ltd Q4FY25; 63% rise in Profits"},"content":{"rendered":"<p>Incorporated in 1981, Emcure Pharmaceuticals<br \/>\nLtd manufactures and markets pharmaceutical products globally<\/p>\n<p>Financial Results:<\/p>\n<p>Emcure Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,116.00 Crores up from \u20b91,771.00 Crore year on year, a rise of 19.48%.<\/p>\n<p>Total Expenses for Q4FY25 of \u20b91,850.00 Crores up from \u20b91,616.00 Crores year on year, a rise of 14.48%.<\/p>\n<p>Consolidated Net Profit of \u20b9197.00 Crores up 62.81% from \u20b9121.00 Crores in the same quarter of the previous year.<\/p>\n<p>The Earnings per Share is \u20b99.97, up 56.76% from \u20b96.36 in the same quarter of the previous year.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169072\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png\" alt=\"\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally Financial Results: Emcure Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,116.00 Crores up from \u20b91,771.00 Crore year on year, a rise of 19.48%. Total Expenses for Q4FY25 of \u20b91,850.00 Crores up from \u20b91,616.00 Crores year on year, a rise of 14.48%. Consolidated Net [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169072,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-169071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":168473,"url":"https:\/\/alphastreet.com\/india\/torrent-pharmaceuticals-ltd-q4fy25-11-rise-in-profits\/","url_meta":{"origin":169071,"position":0},"title":"Torrent Pharmaceuticals Ltd Q4FY25; 11% rise in Profits","author":"Chirag Gupta","date":"May 21, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. Financial Results: Torrent Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,959.00 Crores up from \u20b92,745.00 Crore year on year, a rise of 7.8%. Total Expenses for Q4FY25 of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/2-11.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169169,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue-2\/","url_meta":{"origin":169071,"position":1},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 17, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-11.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169156,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-ltd-q4fy25-6-rise-in-revenue\/","url_meta":{"origin":169071,"position":2},"title":"Glenmark Pharmaceuticals Ltd Q4FY25; 6% rise in Revenue","author":"Divyansh_Kasana","date":"July 16, 2025","format":false,"excerpt":"Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. Financial Results: Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b93,256.20 Crores up from \u20b93,062.96 Crore year on year, a rise of 6.31%. Total Expenses for Q4FY25\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/Y.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168418,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-ltd-q4fy25-12-fall-in-profits\/","url_meta":{"origin":169071,"position":3},"title":"Alembic Pharmaceuticals Ltd Q4FY25; 12% fall in Profits","author":"Divyansh_Kasana","date":"May 19, 2025","format":false,"excerpt":"Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities. Financial Results: Alembic Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b91,770.00 Crores up from \u20b91,517.00 Crore year on year, a rise\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/I-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/I-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/I-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/I-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/I-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/I-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169153,"url":"https:\/\/alphastreet.com\/india\/glaxosmithkline-pharmaceuticals-ltd-q4fy25-36-rise-in-profits\/","url_meta":{"origin":169071,"position":4},"title":"Glaxosmithkline Pharmaceuticals Ltd Q4FY25; 36% rise in Profits","author":"Divyansh_Kasana","date":"July 16, 2025","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site) Financial Results: Glaxosmithkline Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b9974.00 Crores up from \u20b9930.00 Crore year on year, a rise of 4.73%. Total Expenses for Q4FY25 of \u20b9657.00 Crores\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/U-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169166,"url":"https:\/\/alphastreet.com\/india\/glaxosmithkline-pharmaceuticals-ltd-q4fy25-36-rise-in-profits-2\/","url_meta":{"origin":169071,"position":5},"title":"Glaxosmithkline Pharmaceuticals Ltd Q4FY25; 36% rise in Profits","author":"Divyansh_Kasana","date":"July 17, 2025","format":false,"excerpt":"GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site) Financial Results: Glaxosmithkline Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b9974.00 Crores up from \u20b9930.00 Crore year on year, a rise of 4.73%. Total Expenses for Q4FY25 of \u20b9657.00 Crores\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169071"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169071\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169072"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}